Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Video

Updated: Jun 28, 2026

Intraoperative Strategy under Complex Vascular Adhesion for Laparoscopic Radical Resection of Bismuth-Corlette Type IIIb Perihilar Cholangiocarcinoma
05:22

Intraoperative Strategy under Complex Vascular Adhesion for Laparoscopic Radical Resection of Bismuth-Corlette Type IIIb Perihilar Cholangiocarcinoma

Published on: February 13, 2026

Cholangiocarcinoma.

Stefania Mosconi1, Giordano D Beretta, Roberto Labianca

  • 1Ospedali Riuniti, Largo Barozzi 1, 24128 Bergamo, Italy.

Critical Reviews in Oncology/Hematology
|November 4, 2008
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

Cholecystitis01:20

Cholecystitis

Cholecystitis is inflammation of the gallbladder, most commonly caused by obstruction of the cystic duct. This blockage prevents bile from draining, leading to gallbladder distension, inflammation, and potentially serious complications. This condition may present acutely or chronically and can happen with or without gallstones.EtiologyAbout 95% of cholecystitis cases are calculous, caused by gallstones blocking the cystic duct, leading to bile accumulation and inflammation of the gallbladder...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

International variation in child healthcare practices and implications for childhood cancer diagnosis: a scoping review and cross-country clinician survey.

European journal of pediatrics·2026
Same author

Neuroblastoma by Stage at Diagnosis and Other Prognostic Factors: The Results of the BENCHISTA Italian Project-A Population-Based Study.

Cancers·2026
Same author

Stage at Diagnosis and International Survival Variation in Childhood Tumors in the BENCHISTA Study.

JAMA network open·2026
Same author

Investigational sites requirements according to trial complexity and intervention level under EU Regulation No. 536/2014.

Journal of cancer policy·2026
Same author

Improving the Connection Between Population-Based and National Clinical Pediatric Cancer Registries-A Pilot Study on Neuroblastoma: The Italian BENCHISTA-Ita Project.

Cancers·2025
Same author

Benchmarking nazionale della sopravvivenza per stadio alla diagnosi dei tumori infantili in Italia (BENCHISTA-ITA): protocollo di studio.

Epidemiologia e prevenzione·2025
Same journal

Estrobolome and the Endocrine-Microbiome Axis in Breast and Endometrial Carcinogenesis.

Critical reviews in oncology/hematology·2026
Same journal

Remodeling the immune microenvironment: Engineering IL-2 variants to overcome clinical bottlenecks in PD-1 inhibitor plus chemotherapy.

Critical reviews in oncology/hematology·2026
Same journal

Neoadjuvant immunotherapy in melanoma: From pathologic response to response-adapted management.

Critical reviews in oncology/hematology·2026
Same journal

DNA polymerase epsilon catalytic subunit (POLE) in cancer: Implications for tumor biology and therapeutic strategies - A comprehensive review.

Critical reviews in oncology/hematology·2026
Same journal

Long non-coding RNAs in triple-negative breast cancer: emerging drivers of tumor biology, prognosis, and drug resistance.

Critical reviews in oncology/hematology·2026
Same journal

Alternative splicing in breast cancer drug resistance: Mechanisms, therapeutic targeting, and clinical translation.

Critical reviews in oncology/hematology·2026
See all related articles

Cholangiocarcinoma, a rare cancer, has a poor prognosis with limited 5-year survival. Complete surgical resection offers the best chance for cure, but most patients present with advanced disease.

Area of Science:

  • Gastroenterology
  • Surgical Oncology
  • Biliary Tract Cancers

Background:

  • Cholangiocarcinoma is an uncommon adenocarcinoma with a historically poor prognosis.
  • While 1-year survival has improved, 5-year survival remains below 5%, highlighting the need for better treatment strategies.
  • Most patients are diagnosed with advanced disease, limiting curative surgical options.

Purpose of the Study:

  • To address frequently asked questions regarding the diagnosis, treatment, and management of cholangiocarcinoma.
  • To provide practical information for clinicians facing daily challenges with cholangiocarcinoma patients.
  • To explore potential roles for adjuvant and neoadjuvant therapies and standard treatments for unresectable or metastatic disease.

Main Methods:

  • Review of current literature and clinical practice guidelines.

Related Experiment Videos

Last Updated: Jun 28, 2026

Intraoperative Strategy under Complex Vascular Adhesion for Laparoscopic Radical Resection of Bismuth-Corlette Type IIIb Perihilar Cholangiocarcinoma
05:22

Intraoperative Strategy under Complex Vascular Adhesion for Laparoscopic Radical Resection of Bismuth-Corlette Type IIIb Perihilar Cholangiocarcinoma

Published on: February 13, 2026

  • Analysis of prognostic factors, including surgical resection and tumor location.
  • Discussion of treatment options for various stages of cholangiocarcinoma.

    • Main Results:

    • Complete surgical resection is the most effective therapy for early-stage cholangiocarcinoma, offering the only chance for cure.
    • Tumor location (proximal vs. distal) does not impact survival if complete resection is achieved.
    • Despite aggressive surgery, high rates of recurrence and metastasis contribute to poor long-term outcomes.

    Conclusions:

    • The prognosis for cholangiocarcinoma remains poor due to high recurrence and metastasis rates, even after aggressive surgical treatment.
    • Further research is needed to determine the optimal role of adjuvant/neoadjuvant therapies and establish standard treatments for advanced disease.
    • This report aims to guide clinical practice from diagnosis through palliative care for cholangiocarcinoma.